Skip to main content

Posts tagged with "Patents and IP"

  • Academia (vs. Industry)

    Researching While Chinese

    One of my basic principles is that “Just because you can mess things up by going in one direction doesn’t mean that you can’t mess them up by doing the opposite”. And we may be proving that one again, with this example being the position of Chinese researchers in the US. I will stipulate up… Read More
  • Patents and IP

    Patents and Prophecy

    Like many industrial scientists, I’ve been dealing with the patent literature for so long that I’m used to its (many) idiosyncrasies. There are large sections of any patent that I just page through as rapidly as possible because they are utterly not worth reading. The parts where the various dosage forms and potential dosing combination… Read More
  • Chemical News

    Automated Route Finding (and Patent Busting)

    Here’s another look at retrosynthesis software, building on the earlier Chematica paper that looked at generating new routes to known compounds. This is a more detailed look at the same idea, using the software to both analyze the existing routes to marketed drugs (and the patent landscape around them) and to come up with new… Read More
  • Patents and IP

    Allergan Brings the Roof Down On Its Head

    In case you missed it, Allergan’s Restasis patent fight took a sudden turn yesterday, when federal judge William Bryson ruled in Texas to invalidate six of the company’s patents. That will not come as welcome news to either Allergan nor to the St. Regis Mohawk Nation, to whom the company (in)famously transferred those patent rights. Up… Read More
  • Business and Markets

    Incyte and Flexus: The Grappling Continues

    A couple of years back, I wrote about a case of accused stolen pharma intellectual property that looked like it would be heading to court. And here we are in 2017, and it’s. . .heading to court. The wheels of the law have been grinding along this whole time in the matter of Incyte and… Read More
  • Patents and IP

    More on the Mighty Mohawk Maneuver

    So now that Allergan has pioneered the technique of avoiding patent challenges by selling said patent rights to an Indian tribe, where do we go from here? There’s no way to take that one back; we’re now an industry where people do such things, lucky us. But is this going to be a feature of… Read More
  • Business and Markets

    Allergan Pulls A Fast One

    Friday brought news of a drug-company maneuver that I had never heard of, and didn’t even realize was possible. First, a bit of background; the stage needs to be set properly. One of Allergan’s products is Restasis, used for dry eyes, which is an opthalmic formulation of cyclosporine. It’s a valuable part of their portfolio… Read More
  • Business and Markets

    Amgen Will See You In Court – Again

    If they ever get around to making movies about drug discovery and development, perhaps someone will take on PCSK9. It has a neat origin in mutated humans, a race to the clinic, big money and big hopes, dramatic uncertainty (will it actually give better cardiovascular outcomes? Stay tuned!), and now it has courtroom scenes, too. Read More
  • Business and Markets

    Merck Loses. Boy, Does Merck Ever Lose.

    The court case between Merck and Gilead has taken the path that it appeared to be heading down after a Merck employee’s testimony was called into question: the judge has thrown out the $200 million dollar patent award to Merck. All that work for nothing, and all because the testimony of a key witness fell apart. Read More
  • Infectious Diseases

    Unclean Hands?

    Well, this doesn’t look good: reports are that the Gilead/Merck hepatitis C inhibitor patent case may be heading back into court under accusations that one of Merck’s patent lawyers (a former med-chemist) lied under oath. The scientist involved, Phil Durette, already had some problems during his testimony the first time around: At tria… Read More